WO2005028462A1 - Solvat acetonique du dimethoxy docetaxel et son procede de preparation - Google Patents
Solvat acetonique du dimethoxy docetaxel et son procede de preparation Download PDFInfo
- Publication number
- WO2005028462A1 WO2005028462A1 PCT/FR2004/002344 FR2004002344W WO2005028462A1 WO 2005028462 A1 WO2005028462 A1 WO 2005028462A1 FR 2004002344 W FR2004002344 W FR 2004002344W WO 2005028462 A1 WO2005028462 A1 WO 2005028462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxy
- acetone
- dimethoxy
- benzoyloxy
- tax
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the present invention relates to the acetone solvate of dimethoxy docetaxel or (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate of 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ , 20-epoxy-1-hydroxy 7 ⁇ , 1 O ⁇ -dimethoxy-9-oxo-tax-11-en-13 ⁇ -yl, and its method of preparation.
- the acetonic solvate of 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ , 20-epoxy-1-hydroxy-7 ⁇ , 10 ⁇ (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate -dimethoxy-9-oxo-tax-1-en-13 ⁇ -yl can be obtained by crystallization of (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate 4-acetoxy-2 ⁇ -benzoyloxy -5 ⁇ , 20-epoxy-1-hydroxy-7 ⁇ , 10 ⁇ -dimethoxy-9-oxo-tax-1-en-13 ⁇ -yl in a mixture of water and acetone followed by drying under reduced pressure of the isolated product .
- the amount of acetone is between 5 and 20 parts by volume (ml) relative to the weight (in gram) of (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate 4 -acetoxy-2 ⁇ -benzoyloxy-5 ⁇ , 20-epoxy-1-hydroxy-7 ⁇ , 10 ⁇ -dimethoxy-9-oxo-tax-11-ene-13 ⁇ -yl (ideally 10).
- the preferred seeding is at a concentration of 60 to 80 g (ideally 68 g) per liter of mixture containing an acetone / water volume ratio of between 65/35 to 75/25 and preferably about 68/32.
- the acetone / water volume mixture at the end of the precipitation is between 70/30 minimum and 30/70 maximum (ideally 45/55).
- the entire crystallization process proceeds in a better manner to practice the invention at 20 ⁇ 5 ° C (ideally 20 ° C).
- the acetonic solvate of 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ , 20-epoxy-1-hydroxy-7 ⁇ , 10 ⁇ -dimethoxy- (2R, 3S) -3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate The 9-oxo-tax-1-ene-13 ⁇ -yl which crystallizes is separated, preferably by filtration or centrifugation.
- the drying is carried out under reduced pressure, generally between 0.5 and 30 kPa, preferably close to 0.7 kPa at a temperature between 30 and 60 ° C, preferably close to 40 ° C.
- the drying of the product has been studied.
- An average value of the acetone content is 7% which represents approximately the stoichiometry in acetone which is 6.5% for a solvate to a molecule of acetone.
- Example 1 To a solution of 207 g of 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ , 20-epoxy-1-hydroxy-7 ⁇ , 10 ⁇ -dimethoxy-9-oxo-tax-11-en-13 ⁇ -yl, about 92% by weight in about 2 liters of acetone is added at 20 ⁇ 5 ° C room temperature, 940 ml of purified water and then inoculated with a suspension of 2 g of (2R, 3S) -3-tert-butoxycarbonylamino 4-Acetoxy-2 ⁇ -benzoyloxy- ⁇ , 20-epoxy-1-hydroxy-7 ⁇ , 10 ⁇ -dimethoxy-9-oxo-tax-11-ene-13 ⁇ -yl -2-hydroxy-3-phenylpropionate isolated in acetone / water in a mixture of 20 ml of water and 20 ml of acetone.
- the analyzes are carried out on the Bruker D5000 diffractometer equipped with an Anton-Paar TTK temperature chamber.
- the reflection assembly has a Bragg-Brentano focusing geometry ( ⁇ - ⁇ ).
- the powder is deposited on a hollow aluminum sample holder.
- Variable front slots keep a constant illumination surface of the sample.
- a 1 mm collimator limits diffusion between the tube and the measuring chamber.
- the linear Braun 5O M multichannel detector is used. It has a detection window with a width of 10 ° at an angle 2/9.
- the recording conditions of the diagrams are as follows: scanning from 1.5 to 50 degrees in 2 ⁇ , counting time of 30 seconds per degree in 2 ⁇ , under the ambient conditions of temperature, pressure and relative humidity.
- FIG. 1 represents the reference DRXP diagram of the solvate form with acetone (form A) of the product of example 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA06002639A MXPA06002639A (es) | 2003-09-19 | 2004-09-16 | Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion. |
AU2004274212A AU2004274212B2 (en) | 2003-09-19 | 2004-09-16 | Dimethoxy docetaxel acetone solvate et method for the preparation thereof |
JP2006526663A JP5010279B2 (ja) | 2003-09-19 | 2004-09-16 | ジメトキシドセタキセル・アセトン溶媒和物およびその製造方法 |
ES04787385T ES2403149T4 (es) | 2003-09-19 | 2004-09-16 | Solvato acetónico de dimetoxi docetaxel y su procedimiento de preparación |
DK04787385.6T DK1667986T3 (da) | 2003-09-19 | 2004-09-16 | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf |
KR1020067005396A KR101123588B1 (ko) | 2003-09-19 | 2004-09-16 | 디메톡시 도세탁셀 아세톤 용매화물 및 이의 제조 방법 |
PL04787385T PL1667986T3 (pl) | 2003-09-19 | 2004-09-16 | Solwat acetonowy dimetoksydocetakselu i sposób jego wytwarzania |
BRPI0414492A BRPI0414492A8 (pt) | 2003-09-19 | 2004-09-16 | solvato acetônico do dimetóxi docetaxel e seu processo de preparação |
MEP-117/08A MEP11708A (en) | 2003-09-19 | 2004-09-16 | Dimethoxy docetaxel acetone solvate et method for the preparation thereof |
EP04787385A EP1667986B1 (fr) | 2003-09-19 | 2004-09-16 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
RS20060189A RS54614B1 (en) | 2003-09-19 | 2004-09-16 | Acetone solvate dimethoxy docetaxel and procedure for its production |
YUP-2006/0189A RS20060189A (en) | 2003-09-19 | 2004-09-16 | Dimethoxy docetaxel acetone solvate et method for the preparation thereof |
CA002539309A CA2539309A1 (fr) | 2003-09-19 | 2004-09-16 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
NZ545835A NZ545835A (en) | 2003-09-19 | 2004-09-16 | Dimethoxy docetaxel acetone solvate and method for the preparation thereof |
MEP-2008-117A ME00054B (me) | 2003-09-19 | 2004-09-16 | Acetonski solvati dimetoksi docetaksela i postupci za njihovo dobijanje |
SI200432016T SI1667986T1 (sl) | 2003-09-19 | 2004-09-16 | Acetonski solvat dimetoksi docetaksela in postopek za njegovo pripravo |
IL174240A IL174240A (en) | 2003-09-19 | 2006-03-09 | Dimethoxy docetaxel acetone solvate and method for the preparation thereof |
TNP2006000086A TNSN06086A1 (en) | 2003-09-19 | 2006-03-17 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
NO20061714A NO335997B1 (no) | 2003-09-19 | 2006-04-19 | Dimetoksydocetaksel-acetonsolvat og fremgangsmåte for fremstilling derav |
HK06114182.3A HK1093340A1 (en) | 2003-09-19 | 2006-12-28 | Dimethoxy docetaxel acetone solvate et method for the preparation thereof |
HRP20130322TT HRP20130322T1 (en) | 2003-09-19 | 2013-04-10 | Dimethoxy docetaxel acetone solvate et method for the preparation thereof |
CY2013016C CY2013016I2 (el) | 2003-09-19 | 2013-05-13 | Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του |
HUS1300025C HUS1300025I1 (hu) | 2003-09-19 | 2013-06-07 | Dimetoxidocetaxel aceton-szolvátja és eljárás ennek elõállítására |
BE2013C036C BE2013C036I2 (fr) | 2003-09-19 | 2013-06-13 | |
FR13C0037C FR13C0037I2 (fr) | 2003-09-19 | 2013-07-04 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
NO2015013C NO2015013I1 (no) | 2003-09-19 | 2015-04-22 | Cabazitaxel acetonat, også betegnet acetonsolvat av cabazitaxel eller acetonsolvat av imetoksydocetaxel, eller acetonsolvat av 4-acetoksy-2¿-benzoyloksy-5ß,20-epoksy-1-hydroksy-ß,10ßdimetoksy-9-oksotaks-11-en-13¿-yl (2R,3S)-3-tertbutoksykarbonylamino-2-hydroksy-3-fenylpropionat |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0311016A FR2859996B1 (fr) | 2003-09-19 | 2003-09-19 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
FR0311016 | 2003-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005028462A1 true WO2005028462A1 (fr) | 2005-03-31 |
Family
ID=34224354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2004/002344 WO2005028462A1 (fr) | 2003-09-19 | 2004-09-16 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
Country Status (38)
Country | Link |
---|---|
US (1) | US7241907B2 (fr) |
EP (1) | EP1667986B1 (fr) |
JP (1) | JP5010279B2 (fr) |
KR (1) | KR101123588B1 (fr) |
CN (1) | CN100429207C (fr) |
AR (1) | AR045667A1 (fr) |
AU (1) | AU2004274212B2 (fr) |
BE (1) | BE2013C036I2 (fr) |
BR (1) | BRPI0414492A8 (fr) |
CA (1) | CA2539309A1 (fr) |
CR (1) | CR8292A (fr) |
CY (2) | CY1114575T1 (fr) |
DK (1) | DK1667986T3 (fr) |
ES (1) | ES2403149T4 (fr) |
FR (2) | FR2859996B1 (fr) |
HK (1) | HK1093340A1 (fr) |
HR (1) | HRP20130322T1 (fr) |
HU (1) | HUS1300025I1 (fr) |
IL (1) | IL174240A (fr) |
LU (1) | LU92172I2 (fr) |
MA (1) | MA28045A1 (fr) |
ME (2) | ME00054B (fr) |
MX (1) | MXPA06002639A (fr) |
MY (1) | MY136668A (fr) |
NO (2) | NO335997B1 (fr) |
NZ (1) | NZ545835A (fr) |
PA (1) | PA8612401A1 (fr) |
PE (1) | PE20050870A1 (fr) |
PL (1) | PL1667986T3 (fr) |
PT (1) | PT1667986E (fr) |
RS (2) | RS54614B1 (fr) |
RU (1) | RU2342373C2 (fr) |
SI (1) | SI1667986T1 (fr) |
TN (1) | TNSN06086A1 (fr) |
TW (1) | TWI382022B (fr) |
UA (1) | UA87115C2 (fr) |
WO (1) | WO2005028462A1 (fr) |
ZA (1) | ZA200602255B (fr) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2926551A1 (fr) * | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
WO2010128258A1 (fr) | 2009-05-06 | 2010-11-11 | Sanofi-Aventis | Combinaison antitumorale comprenant le cabazitaxel et la capecitabine |
WO2013024495A1 (fr) * | 2011-08-18 | 2013-02-21 | Dr. Reddys Laboratories Limited | Formulations pharmaceutiques de cabazitaxel |
WO2013088335A1 (fr) | 2011-12-13 | 2013-06-20 | Aventis Pharma S.A. | Forme cristalline de cabazitaxel et procédé pour préparer celle-ci |
WO2013117683A1 (fr) * | 2012-02-10 | 2013-08-15 | Aventis Pharma S.A. | Nouvelles utilisations pédiatriques du cabazitaxel |
WO2013134534A2 (fr) | 2012-03-08 | 2013-09-12 | Plus Chemicals S.A. | Formes à l'état solide de cabazitaxel et procédés pour les préparer |
WO2014015760A1 (fr) | 2012-07-25 | 2014-01-30 | 重庆泰濠制药有限公司 | Forme cristallisée de cabazitaxel et son procédé de fabrication |
EP2743264A1 (fr) | 2012-12-13 | 2014-06-18 | INDENA S.p.A. | Nouvelle forme cristalline de cabazitaxel, procédé de préparation et ses compositions pharmaceutiques |
EP2815749A1 (fr) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique |
US8921411B2 (en) | 2011-04-12 | 2014-12-30 | Plus Chemicals Sa | Solid state forms of cabazitaxel and processes for preparation thereof |
US8927592B2 (en) | 2009-10-29 | 2015-01-06 | Aventis Pharma Sa | Antitumoral use of cabazitaxel |
EP2865675A1 (fr) | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Forme cristalline anhydre de Cabazitaxel, procédé de préparation et ses compositions pharmaceutiques |
EP2865674A1 (fr) | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Formes dissoutes cristallines de Cabazitaxel |
AU2013205442B2 (en) * | 2008-01-17 | 2016-05-12 | Aventis Pharma S.A. | Crystalline forms of dimethoxy docetaxel and methods for preparing same |
US9403785B2 (en) | 2012-01-03 | 2016-08-02 | Shilpa Medicare Limited | Process for preparing amorphous cabazitaxel |
WO2016133387A1 (fr) | 2015-02-17 | 2016-08-25 | Erasmus University Medical Center Rotterdam | Utilisation du cabazitaxel dans le traitement du cancer de la prostate |
WO2016180943A1 (fr) | 2015-05-13 | 2016-11-17 | Aventis Pharma S.A. | Cabazitaxel et son utilisation pour le traitement du cancer |
WO2020249507A1 (fr) | 2019-06-11 | 2020-12-17 | Indena S.P.A. | Forme cristalline anhydre du cabazitaxel, procédé pour sa préparation et compositions pharmaceutiques la contenant |
EP3797834A1 (fr) | 2019-09-25 | 2021-03-31 | Sanofi Mature IP | Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène |
EP3808345A1 (fr) | 2019-10-15 | 2021-04-21 | Sanofi Mature IP | Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène |
US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
US11617752B2 (en) | 2018-05-30 | 2023-04-04 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
US11752154B2 (en) | 2017-09-01 | 2023-09-12 | Ptc Therapeutics Mp, Inc. | Pharmaceutical compositions comprising sepiapterin and uses thereof |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009533330A (ja) * | 2006-03-21 | 2009-09-17 | ドクター レディズ ラボラトリーズ リミテッド | ドセタキセルの多形体およびプロセス |
US7855591B2 (en) * | 2006-06-07 | 2010-12-21 | Atmel Corporation | Method and system for providing a charge pump very low voltage applications |
US7652522B2 (en) * | 2006-09-05 | 2010-01-26 | Atmel Corporation | High efficiency low cost bi-directional charge pump circuit for very low voltage applications |
US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8637466B2 (en) | 2008-08-11 | 2014-01-28 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
CA2708489A1 (fr) * | 2009-10-29 | 2011-04-29 | Aventis Pharma S.A. | Utilisation de cabazitaxel et de prednisone ou de prednisolone pour traiter le cancer de la prostate |
AU2015200149B2 (en) * | 2009-10-29 | 2016-12-01 | Aventis Pharma S.A. | Novel antitumoral use of cabazitaxel |
WO2012088445A1 (fr) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Conjugués promédicaments polymères à plusieurs bras de composés à base de cabazitaxel |
WO2012088422A1 (fr) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Conjugués promédicaments polymères à plusieurs bras de composés à base de taxane |
TWI526437B (zh) * | 2011-09-09 | 2016-03-21 | 台灣神隆股份有限公司 | 卡巴他賽之結晶型 |
US8722900B2 (en) | 2011-10-31 | 2014-05-13 | Scinopharm Taiwan, Ltd. | Process for cabazitaxel, and intermediates thereof |
WO2013065070A1 (fr) | 2011-11-01 | 2013-05-10 | Fresenius Kabi Encology Ltd. | Forme amorphe de cabazitaxel et son procédé de préparation |
EP2785701B1 (fr) * | 2011-11-28 | 2019-01-02 | Fresenius Kabi Oncology Limited | Forme cristalline de carbazitaxel et son procédé de préparation |
CN102675257B (zh) * | 2012-05-10 | 2014-07-02 | 上海金和生物技术有限公司 | 一种卡巴他赛晶体及其制备方法 |
WO2014022237A1 (fr) | 2012-07-31 | 2014-02-06 | Yung Shin Pharm. Ind. Co., Ltd. | Cabazitaxel amorphe |
EP2884963B1 (fr) | 2012-08-15 | 2017-12-27 | Yung Shin Pharm. Ind. Co. Ltd. | Formulation pharmaceutique stable de cabazitaxel |
CN103664836B (zh) * | 2012-09-20 | 2016-04-20 | 齐鲁制药有限公司 | 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法 |
WO2014055493A1 (fr) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Procédés et systèmes s'appliquant à la précipitation de polymères et à la génération de particules |
CN103804323A (zh) * | 2012-11-14 | 2014-05-21 | 上海希迈医药科技有限公司 | 一种卡巴他赛溶剂化物及其制备方法和应用 |
CN103058960B (zh) * | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | 卡巴他赛多晶型形式及其制备方法 |
CN103910698B (zh) * | 2012-12-30 | 2016-01-20 | 上海医药工业研究院 | 卡巴他赛丙酮合物及其结晶 |
CN103910696B (zh) * | 2012-12-30 | 2016-01-20 | 上海医药工业研究院 | 卡巴他赛异丙醚合物及其结晶 |
EP2777691A1 (fr) | 2013-03-14 | 2014-09-17 | Pharmachemie B.V. | Taxoïde - purification des excipients liquides |
WO2015000165A1 (fr) * | 2013-07-04 | 2015-01-08 | 北京新天宇科技开发有限公司 | Produit de transformation stable du mono-acétonate de dimethoxy docetaxel et ses formes cristallines, et leurs procédés de préparation |
CN104277014A (zh) * | 2013-07-04 | 2015-01-14 | 北京新天宇科技开发有限公司 | 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法 |
CN103601704B (zh) * | 2013-11-22 | 2015-05-06 | 石家庄智恒医药科技有限公司 | 无定形卡巴他赛的制备 |
ES2904505T3 (es) | 2015-01-12 | 2022-04-05 | Emcure Pharmaceuticals Ltd | Formulación líquida de cabazitaxel |
US10188626B2 (en) | 2015-11-03 | 2019-01-29 | Cipla Limited | Stabilized cabazitaxel formulations |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030355A1 (fr) | 1995-03-27 | 1996-10-03 | Rhone-Poulenc Rorer S.A. | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
WO1997032869A1 (fr) | 1996-03-06 | 1997-09-12 | Rhone-Poulenc Rorer S.A. | Taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
WO1999025704A1 (fr) | 1997-11-18 | 1999-05-27 | Aventis Pharma S.A. | Procede de preparation de derives de la classe des taxoides |
EP0982027A1 (fr) | 1998-08-17 | 2000-03-01 | Aventis Pharma S.A. | Dérivés taxoides pour traiter les proliférations cellulaires anormales du cerveau |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766635A (en) * | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
US6346543B1 (en) * | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
US6136989A (en) * | 1998-12-30 | 2000-10-24 | Phytogen Life Sciences, Incorporated | Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material |
US5969165A (en) * | 1999-01-07 | 1999-10-19 | 508037 (Nb) Inc. | Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column |
WO2000069840A1 (fr) * | 1999-05-17 | 2000-11-23 | Bristol-Myers Squibb Company | Nouvelles conditions de reaction destinees au clivage des silyl-ethers dans la preparation de paclitaxel (taxol®) et d'analogues de paclitaxel |
CA2468953C (fr) * | 2001-11-29 | 2010-05-11 | Daiichi Pharmaceutical Co., Ltd. | Cristaux de derive de taxane et procede de production associe |
-
2003
- 2003-09-19 FR FR0311016A patent/FR2859996B1/fr not_active Expired - Lifetime
-
2004
- 2004-08-19 PE PE2004000799A patent/PE20050870A1/es not_active Application Discontinuation
- 2004-09-16 EP EP04787385A patent/EP1667986B1/fr active Active
- 2004-09-16 AR ARP040103329A patent/AR045667A1/es not_active Application Discontinuation
- 2004-09-16 CA CA002539309A patent/CA2539309A1/fr not_active Abandoned
- 2004-09-16 PL PL04787385T patent/PL1667986T3/pl unknown
- 2004-09-16 ES ES04787385T patent/ES2403149T4/es active Active
- 2004-09-16 RS RS20060189A patent/RS54614B1/en unknown
- 2004-09-16 SI SI200432016T patent/SI1667986T1/sl unknown
- 2004-09-16 JP JP2006526663A patent/JP5010279B2/ja active Active
- 2004-09-16 ME MEP-2008-117A patent/ME00054B/me unknown
- 2004-09-16 RS YUP-2006/0189A patent/RS20060189A/sr unknown
- 2004-09-16 UA UAA200604360A patent/UA87115C2/ru unknown
- 2004-09-16 ME MEP-117/08A patent/MEP11708A/xx unknown
- 2004-09-16 PA PA20048612401A patent/PA8612401A1/es unknown
- 2004-09-16 CN CNB200480026128XA patent/CN100429207C/zh active Active
- 2004-09-16 KR KR1020067005396A patent/KR101123588B1/ko active IP Right Grant
- 2004-09-16 DK DK04787385.6T patent/DK1667986T3/da active
- 2004-09-16 WO PCT/FR2004/002344 patent/WO2005028462A1/fr active Application Filing
- 2004-09-16 PT PT4787385T patent/PT1667986E/pt unknown
- 2004-09-16 RU RU2006113122/04A patent/RU2342373C2/ru active Protection Beyond IP Right Term
- 2004-09-16 AU AU2004274212A patent/AU2004274212B2/en active Active
- 2004-09-16 NZ NZ545835A patent/NZ545835A/en not_active IP Right Cessation
- 2004-09-16 MX MXPA06002639A patent/MXPA06002639A/es active IP Right Grant
- 2004-09-16 BR BRPI0414492A patent/BRPI0414492A8/pt not_active Application Discontinuation
- 2004-09-17 US US10/944,254 patent/US7241907B2/en active Active
- 2004-09-17 TW TW093128097A patent/TWI382022B/zh active
- 2004-09-17 MY MYPI20043787A patent/MY136668A/en unknown
-
2006
- 2006-03-09 IL IL174240A patent/IL174240A/en active IP Right Grant
- 2006-03-15 CR CR8292A patent/CR8292A/es unknown
- 2006-03-17 ZA ZA200602255A patent/ZA200602255B/en unknown
- 2006-03-17 MA MA28881A patent/MA28045A1/fr unknown
- 2006-03-17 TN TNP2006000086A patent/TNSN06086A1/en unknown
- 2006-04-19 NO NO20061714A patent/NO335997B1/no active Protection Beyond IP Right Term
- 2006-12-28 HK HK06114182.3A patent/HK1093340A1/xx not_active IP Right Cessation
-
2013
- 2013-03-20 LU LU92172C patent/LU92172I2/fr unknown
- 2013-04-10 HR HRP20130322TT patent/HRP20130322T1/hr unknown
- 2013-04-16 CY CY20131100313T patent/CY1114575T1/el unknown
- 2013-05-13 CY CY2013016C patent/CY2013016I2/el unknown
- 2013-06-07 HU HUS1300025C patent/HUS1300025I1/hu unknown
- 2013-06-13 BE BE2013C036C patent/BE2013C036I2/fr unknown
- 2013-07-04 FR FR13C0037C patent/FR13C0037I2/fr active Active
-
2015
- 2015-04-22 NO NO2015013C patent/NO2015013I1/no not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030355A1 (fr) | 1995-03-27 | 1996-10-03 | Rhone-Poulenc Rorer S.A. | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
WO1997032869A1 (fr) | 1996-03-06 | 1997-09-12 | Rhone-Poulenc Rorer S.A. | Taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
WO1999025704A1 (fr) | 1997-11-18 | 1999-05-27 | Aventis Pharma S.A. | Procede de preparation de derives de la classe des taxoides |
EP0982027A1 (fr) | 1998-08-17 | 2000-03-01 | Aventis Pharma S.A. | Dérivés taxoides pour traiter les proliférations cellulaires anormales du cerveau |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2719694A1 (fr) | 2008-01-17 | 2014-04-16 | Aventis Pharma S.A. | Forme cristalline anhydre du diméthoxy docétaxel et ses procédés de préparation |
WO2009115655A2 (fr) * | 2008-01-17 | 2009-09-24 | Aventis Pharma S.A. | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
WO2009115655A3 (fr) * | 2008-01-17 | 2010-04-01 | Aventis Pharma S.A. | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
US8378128B2 (en) | 2008-01-17 | 2013-02-19 | Aventis Pharma Sa | Crystalline forms of dimethoxy docetaxel and methods for preparing the same |
FR2926551A1 (fr) * | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
EA017670B1 (ru) * | 2008-01-17 | 2013-02-28 | Авентис Фарма С.А. | Кристаллические формы диметоксидоцетаксела и способы их получения |
US10160739B2 (en) | 2008-01-17 | 2018-12-25 | Aventis Pharma S.A. | Crystalline forms of dimethoxy docetaxel and methods for preparing the same |
AU2013205442B2 (en) * | 2008-01-17 | 2016-05-12 | Aventis Pharma S.A. | Crystalline forms of dimethoxy docetaxel and methods for preparing same |
US8846959B2 (en) | 2008-01-17 | 2014-09-30 | Aventis Pharma Sa | Crystalline forms of dimethoxy docetaxel and methods for preparing the same |
AU2009227081B2 (en) * | 2008-01-17 | 2013-11-14 | Aventis Pharma S.A. | Crystalline forms of dimethoxy docetaxel and methods for preparing same |
WO2010128258A1 (fr) | 2009-05-06 | 2010-11-11 | Sanofi-Aventis | Combinaison antitumorale comprenant le cabazitaxel et la capecitabine |
FR2945212A1 (fr) * | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant le cabazitaxel et la capecitabine |
US10583110B2 (en) | 2009-10-29 | 2020-03-10 | Sanofi Mature Ip | Antitumoral use of cabazitaxel |
EP2493466B1 (fr) | 2009-10-29 | 2021-03-10 | Sanofi Mature IP | Nouvelle utilisation antitumorale du cabazitaxel |
US10716777B2 (en) | 2009-10-29 | 2020-07-21 | Sanofi Mature Ip | Antitumoral use of cabazitaxel |
US8927592B2 (en) | 2009-10-29 | 2015-01-06 | Aventis Pharma Sa | Antitumoral use of cabazitaxel |
US8921411B2 (en) | 2011-04-12 | 2014-12-30 | Plus Chemicals Sa | Solid state forms of cabazitaxel and processes for preparation thereof |
WO2013024495A1 (fr) * | 2011-08-18 | 2013-02-21 | Dr. Reddys Laboratories Limited | Formulations pharmaceutiques de cabazitaxel |
US9309210B2 (en) | 2011-12-13 | 2016-04-12 | Aventis Pharma S.A. | Crystalline form of cabazitaxel and process for preparing the same |
WO2013088335A1 (fr) | 2011-12-13 | 2013-06-20 | Aventis Pharma S.A. | Forme cristalline de cabazitaxel et procédé pour préparer celle-ci |
US9403785B2 (en) | 2012-01-03 | 2016-08-02 | Shilpa Medicare Limited | Process for preparing amorphous cabazitaxel |
WO2013117683A1 (fr) * | 2012-02-10 | 2013-08-15 | Aventis Pharma S.A. | Nouvelles utilisations pédiatriques du cabazitaxel |
US9394266B2 (en) | 2012-03-08 | 2016-07-19 | IVAX International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
WO2013134534A3 (fr) * | 2012-03-08 | 2013-12-05 | Plus Chemicals S.A. | Formes à l'état solide de cabazitaxel et procédés pour les préparer |
WO2013134534A2 (fr) | 2012-03-08 | 2013-09-12 | Plus Chemicals S.A. | Formes à l'état solide de cabazitaxel et procédés pour les préparer |
EP3067348A1 (fr) | 2012-07-25 | 2016-09-14 | Chongqing Taihao Pharmaceutical Co. Ltd. | Forme cristalline du cabazitaxel et son procédé de préparation |
US9353076B2 (en) | 2012-07-25 | 2016-05-31 | Chongqing Taihao Pharmaceutical Co., Ltd. | Crystal form of cabazitaxel and preparation method thereof |
WO2014015760A1 (fr) | 2012-07-25 | 2014-01-30 | 重庆泰濠制药有限公司 | Forme cristallisée de cabazitaxel et son procédé de fabrication |
EP2743264A1 (fr) | 2012-12-13 | 2014-06-18 | INDENA S.p.A. | Nouvelle forme cristalline de cabazitaxel, procédé de préparation et ses compositions pharmaceutiques |
EP2815749A1 (fr) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique |
EP2865675A1 (fr) | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Forme cristalline anhydre de Cabazitaxel, procédé de préparation et ses compositions pharmaceutiques |
WO2015058961A1 (fr) | 2013-10-23 | 2015-04-30 | Indena S.P.A. | Forme anhydre cristalline du cabazitaxel, son procédé de préparation et ses compositions pharmaceutiques |
WO2015058960A1 (fr) | 2013-10-23 | 2015-04-30 | Indena S.P.A. | Formes cristallines de solvate du cabazitaxel |
EP2865674A1 (fr) | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Formes dissoutes cristallines de Cabazitaxel |
WO2016133387A1 (fr) | 2015-02-17 | 2016-08-25 | Erasmus University Medical Center Rotterdam | Utilisation du cabazitaxel dans le traitement du cancer de la prostate |
WO2016180943A1 (fr) | 2015-05-13 | 2016-11-17 | Aventis Pharma S.A. | Cabazitaxel et son utilisation pour le traitement du cancer |
US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
US11773097B2 (en) | 2016-11-29 | 2023-10-03 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
US11752154B2 (en) | 2017-09-01 | 2023-09-12 | Ptc Therapeutics Mp, Inc. | Pharmaceutical compositions comprising sepiapterin and uses thereof |
US11617752B2 (en) | 2018-05-30 | 2023-04-04 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
WO2020249507A1 (fr) | 2019-06-11 | 2020-12-17 | Indena S.P.A. | Forme cristalline anhydre du cabazitaxel, procédé pour sa préparation et compositions pharmaceutiques la contenant |
EP3797834A1 (fr) | 2019-09-25 | 2021-03-31 | Sanofi Mature IP | Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène |
EP3808345A1 (fr) | 2019-10-15 | 2021-04-21 | Sanofi Mature IP | Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1667986B1 (fr) | Solvat acetonique du dimethoxy docetaxel et son procede de preparation | |
EP0770070B1 (fr) | Procede de preparation du trihydrate du (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,7beta,10beta-trihydroxy-9-oxo-tax-11-en-13alpha-yle | |
FR2467211A1 (fr) | Solvats d'ethers alicycliques et d'acide syn-7-(2-(2-amino-4-thiazolyl)-2-methoxyimino) acetamido-3-acetoxymethyl-3-cephem-4-carboxylique, leur preparation et leur utilisation pour la preparation de l'acide libre et de ses sels | |
FR2662441A1 (fr) | Procede de preparation enantioselective de derives de la phenylisoserine. | |
EP2247582A2 (fr) | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation | |
EP0805806B1 (fr) | Procede de preparation du trihydrate du (2r,3s)-3-benzoylamino-2-hydroxy-3-phenylpropionate de 4,10-diacetoxy-2alfa-benzoyloxy-beta,20-epoxy-beta-dihydroxy-9-oxo-tax-11-en-beta-yle | |
Murphy et al. | Investigation of the synthetic and mechanistic aspects of the highly stereoselective transformation of α-thioamides to α-thio-β-chloroacrylamides | |
BE875053A (fr) | Composes analogues aux cephalosporines | |
FR2510991A1 (fr) | Procede pour la preparation de methacrylamides et d'acrylamides n-substitues | |
WO2000059859A1 (fr) | Procede de preparation des fluoroformiates aliphatiques | |
FR2573069A1 (fr) | Nouveaux derives halogenocyclopropaniques, notamment acetals d'halogeno-2 fluoro-2 cyclopropanones, leur procede d'obtention et leur application a la fabrication de fluoro-2 acrylates d'alkyle ou d'aryle | |
KR100367564B1 (ko) | 세파로스포린 결정 및 그의 제조방법 | |
CN109517020B (zh) | Delta-9,11-羟基黄体酮的合成方法 | |
CA2689466A1 (fr) | Dissolution directe du docetaxel dans un solvant dans le polysorbate 80 | |
BE565025A (fr) | ||
FR2477552A1 (fr) | Synthese du chlorhydrate de daunosamine et produits intermediaires utilises pour cette synthese | |
Mazières et al. | Etude D'heterocycles Germanies Synthetises a Partir de L'acide Salicylique et D'acides Derives | |
FR2667318A1 (fr) | Procede de synthese de monohalogenoalkylferrocenes et nouveaux monohalogenoalkylferrocenes. | |
JPH04273895A (ja) | ステロイド誘導体 | |
JPS63135400A (ja) | 24−ヒドロキシ−コレスタ−5−エン類の製造法 | |
FR2508448A1 (fr) | Monohydrate de cimetidine et procede pour sa preparation | |
BE565024A (fr) | ||
FR2771410A1 (fr) | Procede de fabrication de thioesters methacryliques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480026128.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG UZ VC YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004787385 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2006000116 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/002639 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 174240 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 545835 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006500533 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2006-008292 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2539309 Country of ref document: CA Ref document number: KE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/02255 Country of ref document: ZA Ref document number: 06027350 Country of ref document: CO Ref document number: 944/CHENP/2006 Country of ref document: IN Ref document number: P-2006/0189 Country of ref document: YU Ref document number: 200602255 Country of ref document: ZA Ref document number: 2006526663 Country of ref document: JP Ref document number: 1020067005396 Country of ref document: KR Ref document number: 2004274212 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004274212 Country of ref document: AU Date of ref document: 20040916 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004274212 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006113122 Country of ref document: RU Ref document number: 1200600617 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004787385 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067005396 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0414492 Country of ref document: BR |